[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485420":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":32,"responsibleParty":49,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"De-escalated radiotherapy",null,[12],"Radiation: Intensity-Modulated Radiation Therapy (IMRT)",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"RADIATION","Intensity-Modulated Radiation Therapy (IMRT)","IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.",[9],[20],{"name":21,"affiliation":22,"role":23},"Eric Chen, MD","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","877-827-8839","ucstudy@uci.edu",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":10},"University of California Irvine Medical",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Chao Family Comprehensive Cancer Center, University of California, Irvine","RECRUITING","Orange","California","92868","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-117.85311,33.78779,{"lat":45,"lon":44},[48],{"name":21,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":23,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Eric Chen","Assistant Professor","100485420","de-escalated-radiation-for-human-papillomavirus-positive-squamous-cell-carcinoma-of-the-oropharynx-100485420",false,"NCT05600842","De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx","Inclusion Criteria:\n\n* Pathologically (histologically or cytologically) proven (from primary lesion and\u002For lymph nodes) diagnosis of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. HPV-positivity will be defined as tumors that are p16-positive by immunohistochemistry. Numerous studies have demonstrated near 100% agreement between p16 and HPV for patients with oropharyngeal cancer. As such, the use of p16 has been accepted as an appropriate surrogate for HPV status.\n* Clinical stage I, II, or III disease (AJCC Eighth Edition); Note: Patients with M1 tumors (distant metastases) are not eligible;\n* History\u002Fphysical examination within 6 weeks prior to registration, including assessment of weight and recent weight loss;\n* Age ≥ 18;\n* PET\u002FCT within 6 weeks prior to registration;\n* Patients must sign a study-specific informed consent form prior to study entry.\n* Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.\n\nExclusion Criteria:\n\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years;\n* Patients who have had initial surgical treatment other than the diagnostic biopsy of the primary site or nodal sampling of the neck disease are excluded;\n* Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable;\n* Receipt of prior radiotherapy that would result in overlap with proposed field.","ALL","18 Years",{"count":61,"type":62},111,"ESTIMATED","2 Years","OBSERVATIONAL","This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.",[67],"HPV Positive Oropharyngeal Squamous Cell Carcinoma","2026-04-29",{"date":70,"type":71},"2026-05-05","ACTUAL",{"date":73,"type":71},"2022-11-03",{"date":75,"type":62},"2026-11",{"name":5,"class":6},1]